<code id='110CC39907'></code><style id='110CC39907'></style>
    • <acronym id='110CC39907'></acronym>
      <center id='110CC39907'><center id='110CC39907'><tfoot id='110CC39907'></tfoot></center><abbr id='110CC39907'><dir id='110CC39907'><tfoot id='110CC39907'></tfoot><noframes id='110CC39907'>

    • <optgroup id='110CC39907'><strike id='110CC39907'><sup id='110CC39907'></sup></strike><code id='110CC39907'></code></optgroup>
        1. <b id='110CC39907'><label id='110CC39907'><select id='110CC39907'><dt id='110CC39907'><span id='110CC39907'></span></dt></select></label></b><u id='110CC39907'></u>
          <i id='110CC39907'><strike id='110CC39907'><tt id='110CC39907'><pre id='110CC39907'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          knowledge

          author:leisure time    - browse:38
          Stock exchange
          Drew Angerer/Getty Images

          Viking Therapeutics said Tuesday that its closely watched oral obesity drug had succeeded in an early-stage trial and that it planned to advance the medicine into the next phase of development. 

          The top-line results released Tuesday were only from a Phase 1 study, which primarily focuses on a drug’s safety. But Viking said that in the study, its medicine led to a roughly 3.3% placebo-adjusted average weight loss after four weeks and that it showed no safety issues.

          advertisement

          In preview notes, analysts had said that investors would want to see between 3% and 4% placebo-adjusted weight loss. Shares of San Diego-based Viking were up more than 20% in pre-market trading Tuesday.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge